[Amiodarone and secondary prevention. The EMIAT study].
The EMIAT is a randomized, double-blind trial versus placebo, designed to evaluate the efficacy of amiodarone in the prevention of total mortality in patients with left ventricular ejection fraction of under 40% after myocardial infarction. This multicenter European trial initiated by SANOFI Research in association with the Arrhythmia Working Group of the European Society of Cardiology, is part of a larger program of evaluation (3,400 patients) of the benefit-risk ratio of the use of amiodarone for secondary prevention in high risk patients.